References

Formulation and clinical translation of inhalable nanomedicines for the treatment and prevention of pulmonary infectious diseases

10.1007/s13346-025-01861-5 · 2025 · External reference

Nanoparticle-containing lyophilized dry powder inhaler formulations optimized using central composite design with improved aerodynamic parameters and redispersibility

10.1080/10837450.2023.2166066 · 2023 · External reference

Design and fabrication of a dual-drug loaded nano-platform for synergistic anticancer and cytotoxicity effects on the expression of leptin in lung cancer treatment

2022 · External reference

Leucine as an excipient in spray dried powder for inhalation

10.1016/j.drudis.2021.04.009 · 2021 · External reference

Nanocarrier-mediated drug delivery via inhalational route for lung cancer therapy: a systematic and updated review

10.1208/s12249-024-02758-1 · 2024 · External reference

Co-encapsulation of drugs for topical application-a review

10.3390/molecules28031449 · 2023 · External reference

Pulmonary drug delivery applications of natural polysaccharide polymer derived nano/micro-carrier systems: a review

10.1016/j.ijbiomac.2022.09.116 · 2022 · External reference

Drug combinations for inhalation: current products and future development addressing disease control and patient compliance

10.1016/j.ijpharm.2023.123070 · 2023 · External reference

A novel combined dry powder inhaler comprising nanosized ketoprofen-embedded mannitol-coated microparticles for pulmonary inflammations: development, in vitro-in silico characterization, and cell line evaluation

10.3390/ph17010075 · 2024 · External reference

Comprehensive aerodynamic and physicochemical stability evaluations of nanocrystal-based dry powder inhalers: the role of mannitol and leucine in enhancing performance

10.3390/pharmaceutics17040436 · 2025 · External reference

Systematic development and characterization of inhalable dry powder containing polymeric lipid hybrid nanocarriers co-loaded with ABCB1 shRNA and docetaxel using QbD approach

10.1016/j.jddst.2021.102903 · 2021 · External reference

Pulmonary delivery of antitubercular drugs using spray-dried lipid-polymer hybrid nanoparticles

10.3109/21691401.2015.1062389 · 2016 · External reference

Development and characterization of PLA nanoparticles for pulmonary drug delivery: co-encapsulation of theophylline and budesonide, a hydrophilic and lipophilic drug

10.1016/j.jddst.2019.101128 · 2019 · External reference

Deletion of the tissue response against alginate-pll capsules by temporary release of co-encapsulated steroids

10.1016/j.biomaterials.2004.07.017 · 2005 · External reference

The application of quality by design framework in the pharmaceutical development of dry powder inhalers

10.1016/j.ejps.2017.10.042 · 2018 · External reference

“Nano-in-micro” structured dry powder inhalers for pulmonary delivery: advances and challenges

10.1016/j.jddst.2024.105648 · 2024 · External reference

Nanocarriers made from non-ionic surfactants or natural polymers for pulmonary drug delivery

10.2174/1381612822666160418121700 · 2016 · External reference

Mycobacterium tuberculosis: an adaptable pathogen associated with multiple human diseases

10.3389/fcimb.2018.00158 · 2018 · External reference

Inhalable nanoparticle-based dry powder formulations for respiratory diseases: challenges and strategies for translational research

10.1208/s12249-023-02559-y · 2023 · External reference

Inhalable nanoparticle-based dry powder formulations for respiratory diseases: challenges and strategies for translationalresearch

10.1208/s12249-023-02559-y · 2023 · External reference

Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis

2018 · External reference

Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants

10.1016/j.ijpharm.2010.11.021 · 2011 · External reference

Lipid-based particle engineering via spray-drying for targeted delivery of antibiotics to the lung

10.1016/j.ijpharm.2023.123201 · 2023 · External reference

Inhalable formulation based on lipid–polymer hybrid nanoparticles for the macrophage targeted delivery of roflumilast

10.1021/acs.biomac.2c00576 · 2022 · External reference

Regulatory considerations, challenges and risk-based approach in nanomedicine development

10.2174/0929867328666210406115529 · 2021 · External reference

PLGA-based nanoparticles: an overview of biomedical applications

10.1016/j.jconrel.2012.01.043 · 2012 · External reference

A quality by design framework for capsule-based dry powder inhalers

10.3390/pharmaceutics13081213 · 2021 · External reference

Dynamics of aerosol generation and release – dry powder inhaler performance considerations

10.1016/j.jaerosci.2020.105673 · 2021 · External reference

Scientific and regulatory activities initiated by the U.S. food and drug administration to foster approvals of generic dry powder inhalers: quality perspective

10.1016/j.addr.2022.114519 · 2022 · External reference

Biocompatible biodegradable polymeric nanocarriers in dry powder inhalers (DPIs) for pulmonary inhalation delivery

10.1007/s40005-024-00671-0 · 2024 · External reference

Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment

10.1016/j.ejpb.2014.09.012 · 2014 · External reference

Co-spraying of carriers (mannitol-lactose) as a method to improve aerosolization performance of salbutamol sulfate dry powder inhaler

10.1007/s13346-020-00707-6 · 2020 · External reference

Nanomedicines for pulmonary drug delivery: overcoming barriers in the treatment of respiratory infections and lung cancer

10.3390/pharmaceutics16121584 · 2024 · External reference

The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems–a review

10.1016/j.ijpharm.2011.05.049 · 2011 · External reference

Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer

10.1038/s41467-025-58312-5 · 2025 · External reference

Treatable traits, combination inhaler therapy and the future of asthma management

10.1111/resp.14556 · 2023 · External reference

Development and characterization of lung surfactant-coated polymer nanoparticles for pulmonary drug delivery

10.1016/j.bioadv.2023.213430 · 2023 · External reference

Fasudil and SOD packaged in peptide-studded-liposomes: properties, pharmacokinetics and ex-vivo targeting to isolated perfused rat lungs

10.1016/j.ijpharm.2015.04.031 · 2015 · External reference

A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases

10.1186/s12951-022-01307-x · 2022 · External reference

Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer

10.18632/oncotarget.6243 · 2015 · External reference

Recent developments in lactose blend formulations for carrier-based dry powder inhalation

10.1016/j.addr.2022.114527 · 2022 · External reference

Spray-dried nanoparticle-in-microparticle as inhalable dry powder formulation for pulmonary delivery of proteins

10.1016/j.jddst.2026.108316 · 2026 · External reference

10.1016/j.jddst.2024.106183

10.1016/j.jddst.2024.106183 · External reference

Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery–a review for multidisciplinary researchers

10.1016/j.medengphy.2011.12.025 · 2012 · External reference

Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery – a review for multidisciplinary researchers

10.1016/j.medengphy.2011.12.025 · 2012 · External reference

Dry powder inhaler design and particle technology in enhancing pulmonary drug deposition: challenges and future strategies

10.1007/s40199-024-00520-3 · 2024 · External reference

Development of chitosan-based nanoparticles for pulmonary delivery of itraconazole as dry powder formulation

10.1016/j.powtec.2012.01.045 · 2012 · External reference

Lipid polymer hybrid nanoparticles against lung cancer and their application as inhalable formulation

10.1080/17435889.2024.2387530 · 2024 · External reference

The use of amikacin liposome inhalation suspension (arikayce) in the treatment of refractory nontuberculous mycobacterial lung disease in adults

10.2147/dddt.s146111 · 2020 · External reference

Spray-dried inhalable nano-embedded microparticles of isoniazid and pyridoxine hydrochloride for pulmonary tuberculosis

10.1039/d5pm00118h · 2025 · External reference

Spray-dried inhalable nano-embedded microparticles of isoniazid and pyridoxine hydrochloride for pulmonary tuberculosis

10.1039/d5pm00118h · 2026 · External reference

Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles

10.1016/j.ejpb.2020.10.010 · 2020 · External reference

10.21203/rs.3.rs-8275947/v1

10.21203/rs.3.rs-8275947/v1 · External reference

Multifunctional nanoparticle-mediated combining therapy for human diseases

10.1038/s41392-023-01668-1 · 2024 · External reference

Powder production and particle engineering for dry powder inhaler formulations

10.2174/1381612821666150820111134 · 2015 · External reference

The influence of carrier type, physical characteristics, and blending techniques on the performance of dry powder inhalers

2022 · External reference

Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier

10.3390/polym3031377 · 2011 · External reference

Spray drying for the preparation of nanoparticle-based drug formulations as dry powders for inhalation

10.3390/pr8070788 · 2020 · External reference

10.3390/ph17121628

10.3390/ph17121628 · External reference

Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities

10.1038/aps.2017.34 · 2017 · External reference

An overview on spray-drying of protein-loaded polymeric nanoparticles for dry powder inhalation

10.3390/pharmaceutics12111032 · 2020 · External reference

Hyaluronic acid nanoparticles with parameters required for in vivo applications: from synthesis to parametrization

10.1021/acs.biomac.4c00370 · 2024 · External reference

Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine

10.3109/1061186x.2015.1052072 · 2015 · External reference

Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients

10.1016/j.ejpb.2008.06.013 · 2008 · External reference

Co-delivery of metformin and silibinin in dual-drug loaded nanoparticles synergistically improves chemotherapy in human non-small cell lung cancer A549 cells

10.1016/j.jddst.2021.102752 · 2021 · External reference

Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis

10.1080/03639045.2019.1609494 · 2019 · External reference

Developing dry powder inhaler formulations

10.1089/jamp.2024.29109.davm · 2024 · External reference

Engineering of inhalable nano-in-microparticles for co-delivery of small molecules and miRNAs

10.1186/s11671-023-03781-0 · 2023 · External reference

Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols

10.1039/d0ra07203f · 2020 · External reference

Inhalable dry powder nano-formulations: advancing lung disease therapy-a review

10.3389/fnano.2024.1403313 · 2024 · External reference

Artificial intelligence in drug formulation and development: applications and future prospects

10.2174/0113892002265786230921062205 · 2023 · External reference

A multilayer hollow nanocarrier for pulmonary co-drug delivery of methotrexate and doxorubicin in the form of dry powder inhalation formulation

10.1016/j.msec.2019.02.009 · 2019 · External reference

Inhalable poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulating all-trans-retinoic acid (ATRA) as a host-directed, adjunctive treatment for Mycobacterium tuberculosis infection

10.1016/j.ejpb.2018.10.020 · 2019 · External reference

10.1164/rccm.201604-0700oc

10.1164/rccm.201604-0700oc · External reference

Formulation and in vitro and in silico characterization of “nano-in-micro” dry powder inhalers containing meloxicam

10.3390/pharmaceutics13020211 · 2021 · External reference

A review on micro and nanoengineering in powder-based pulmonary drug delivery

10.1016/j.ijpharm.2024.124248 · 2024 · External reference

Inhalable dry powder containing lipid polymer hybrid nanoparticles of nintedanib esylate: in vitro and in vivo evaluations

10.1016/j.jddst.2023.104716 · 2023 · External reference

Nano-formulations for pulmonary delivery: past, present, and future perspectives

10.3390/pharmaceutics16020161 · 2024 · External reference

Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis

10.1016/j.ijpharm.2013.04.069 · 2013 · External reference

Characterization of dry powder inhaler performance through experimental methods

10.1016/j.addr.2022.114518 · 2022 · External reference

Using chitosan, hyaluronic acid, alginate, and gelatin-based smart biological hydrogels for drug delivery in oral mucosal lesions: a review

10.1016/j.ijbiomac.2023.126573 · 2023 · External reference

Particle engineering in dry powders for inhalation

10.1016/j.ejps.2022.106158 · 2022 · External reference

Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung

10.1016/j.ijpharm.2003.09.041 · 2004 · External reference

Nano-in-micro dry powder formulations combining azithromycin and menadione as adjuvant against pulmonary P. aeruginosa infections

10.1016/j.ijpharm.2026.126965 · 2026 · External reference

Effect of lipidic excipients on the particle properties and aerosol performance of high drug load spray dried particles for inhalation

10.1016/j.xphs.2021.09.004 · 2022 · External reference

Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation

10.1016/j.ijpharm.2018.04.034 · 2018 · External reference

Dry powder form of polymeric nanoparticles for pulmonary drug delivery

10.2174/1381612822666160128150449 · 2016 · External reference

Nano-based carriers for pulmonary drug delivery: a review on the available drug delivery applications and toxicity issues

10.1016/j.jddst.2024.105381 · 2024 · External reference

The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules

10.1016/j.ejpb.2012.10.015 · 2013 · External reference

Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach

10.1016/j.ijpharm.2011.09.018 · 2011 · External reference

PLGA-based co-delivery nanoformulations: overview, strategies, and recent advances

10.3390/pharmaceutics17121613 · 2025 · External reference

Quality by design in pulmonary drug delivery: a review on dry powder inhaler development, nanotherapy approaches, and regulatory considerations

10.1208/s12249-024-02900-z · 2024 · External reference

Do all dry powder inhalers show the same pharmaceutical performance?

10.1111/j.1368-504x.2005.00721.x · 2005 · External reference

Dry powder inhaler formulation

10.4187/respcare.05501209 · 2005 · External reference

Consistent pulmonary drug delivery with whole lung deposition using the aerosphere inhaler: a review of the evidence

10.2147/copd.s274846 · 2021 · External reference

Pharmaceutical particle engineering via spray drying

10.1007/s11095-007-9475-1 · 2008 · External reference

Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. aeruginosa biofilm eradication

10.1016/j.ijpharm.2024.124208 · 2024 · External reference

A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles

10.1016/j.ijpharm.2011.12.045 · 2012 · External reference

A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid–polymer hybrid nanoparticles

10.1016/j.ijpharm.2011.12.045 · 2012 · External reference

Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: a 12-month open-label extension clinical trial

10.1513/annalsats.202008-925oc · 2021 · External reference

Pulmonary delivery by exploiting doxorubicin and cisplatin co-loaded nanoparticles for metastatic lung cancer therapy

10.1016/j.jconrel.2018.12.013 · 2019 · External reference

siRNA nanoparticle dry powder formulation with high transfection efficiency and pulmonary deposition for acute lung injury treatment

10.1021/acsami.4c04241 · 2024 · External reference

Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles

10.1016/j.ijpharm.2022.121758 · 2022 · External reference

Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

10.1186/s12951-020-00703-5 · 2020 · External reference

Insights into the mechanisms of interaction between inhalable lipid-polymer hybrid nanoparticles and pulmonary surfactant

10.1016/j.jcis.2022.11.059 · 2023 · External reference

Inhalable composite microparticles containing siRNA-loaded lipid-polymer hybrid nanoparticles: saccharides and leucine preserve aerosol performance and long-term physical stability

2022 · External reference

pH-responsive nanoparticles for cancer immunotherapy: a brief review

10.3390/nano10081613 · 2020 · External reference

Dry powder inhaler formulation of lipid-polymer hybrid nanoparticles via electrostatically-driven nanoparticle assembly onto microscale carrier particles

10.1016/j.ijpharm.2012.05.036 · 2012 · External reference

Dry powder inhaler formulation of lipid–polymer hybrid nanoparticles via electrostatically-driven nanoparticle assembly onto microscale carrier particles

10.1016/j.ijpharm.2012.05.036 · 2012 · External reference

Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: spray drying versus spray freeze drying preparation

10.1016/j.ijpharm.2015.12.072 · 2016 · External reference

Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by P. aeruginosa

10.1016/j.ijpharm.2021.121160 · 2021 · External reference

Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections

10.1016/j.ijpharm.2019.118915 · 2020 · External reference

Optimization of inhalable liposomal powder formulations and evaluation of their in vitro drug delivery behavior in Calu-3 human lung epithelial cells

10.1016/j.ijpharm.2020.119570 · 2020 · External reference

Advancements in chitosan-based nanoparticles for pulmonary drug delivery

10.3390/polym15183849 · 2023 · External reference

Enhancing lung recovery: inhaled poly(lactic-co-glycolic) acid encapsulating FTY720 and nobiletin for lipopolysaccharide-induced lung injury, with advanced inhalation tower technology

10.1021/acsnano.3c12532 · 2025 · External reference

Stimuli-responsive nanocarriers for therapeutic applications in cancer

10.20892/j.issn.2095-3941.2020.0496 · 2021 · External reference

Development and investigation of dual potent anticancer drug-loaded nanoparticles for the treatment of lung cancer therapy

10.1016/j.procbio.2021.03.018 · 2021 · External reference

Inhalable nanocomposite microparticles with enhanced dissolution and superior aerosol performance

10.1021/acs.molpharmaceut.0c00390 · 2020 · External reference

Artificial intelligence-driven innovations in pharmaceutical development and drug delivery systems

10.2174/0115680266373236250411060857 · 2025 · External reference